For instance, in stroke and neurodegenerative diseases, factors such as systemic inflammation, prolonged immobility, sarcopenia, and overall metabolic dysfunction—all hallmarks of these conditions—could directly suppress the production or release of irisin from muscle tissue. This evidence concerns the gene FNDC5 and stroke disorder.